YL-202 is under clinical development by Suzhou Medilink Therapeutics and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how YL-202’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
YL-202 overview
YL-202 is under development for the treatment of solid tumors, advanced or metastatic non-small cell lung cancer and advanced or metastatic HR-positive and HER2-negative breast cancer (HER2- Breast Cancer), metastatic breast cancer, head and neck squamous cell carcinoma, colorectal cancer, HER2-positive gastric cancer, cervical cancer, triple-negative breast cancer and ovarian cancer. The drug candidate is a antibody drug conjugate composed of human anti-HER3 antibody, protease-cleavable linker, and a novel topoisomerase I inhibitor. The drug candidate is administered through intravenous route.
Suzhou Medilink Therapeutics overview
Suzhou Medilink Therapeutics (Suzhou Medilink) is a biotech company focusing on antibody-drug conjugate research & development. Suzhou Medilink is headquartered in Suzhou, Jiangsu, China.
For a complete picture of YL-202’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
